Beta-2 adrenergic agonist
Clenbuterol
Clenbuterol after one dose: 50% at ~35 h, 25% at 70 h, 12.5% at 105 h.
Drawn from the half-life in the app's model, ~35 h. The model's figures
- Compound
- Clenbuterol
- Symbol
- CLN
- Family
- Metabolic and mitochondrial peptides
- Parts
- 14
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Clenbuterol is an oral beta-2 adrenergic agonist that the German Spiropent label describes as a direct-acting sympathomimetic with predominant beta-2 selectivity.1 The label's indication is the symptomatic treatment of chronic obstructive airway diseases with reversible airway narrowing, and it adds that the tablets are not suited to symptom-based treatment of an acute asthma attack.1 The app lists clenbuterol as a beta-2 agonist and notes that its product Spiropent is approved as an asthma medication in some countries. In the United States, a DailyMed search for clenbuterol returned two labels, a clenbuterol HCl powder and Ventipulmin syrup; the Ventipulmin label states "For oral use in horses only" and "Not for use in humans," and the powder label was not read.3
Hostrup and colleagues (University of Copenhagen, Journal of Physiology, 2025) describe clenbuterol as "widely abused because of its purported" fat-burning and muscle-building effects that "remains unexplored in randomized controlled trials".4 In their trial, 11 healthy men took clenbuterol or placebo in two 2 week cycles, and lean mass was 0.91 kg higher with clenbuterol, with no effect on fat mass, a 7% fall in maximal oxygen uptake and a 4% fall in exercise capacity.4 A small randomised trial in patients with chronic heart failure (Kamalakkannan and colleagues, Journal of Heart and Lung Transplantation, 2008) reported a significant rise in lean mass, with endurance and exercise duration decreasing after clenbuterol.5 A 2026 trial from the same Copenhagen group in 32 healthy men and women added resistance training, and reported a 1.7 kg larger lean mass gain with clenbuterol over 8 weeks.6 The app grades the evidence for clenbuterol as moderate.
How it works
Sources in this part
The German label states that clenbuterol relaxes smooth muscle in the bronchi and blood vessels, and that these effects are mediated by activation of adenylate cyclase, with accumulation of cyclic AMP.1 The label also reports that muscle hypertrophy of striated muscle has been described in preclinical studies with high doses, that the mechanism is not yet clarified, and that the significance of these findings for humans is unclear.1 In the 2025 trial, muscle biopsies showed that clenbuterol "markedly activated muscle protein kinase A" and phosphorylated ribosomal protein S6, but "this effect declined during the 2 week cycle".4 The authors interpret the decline as tolerance in beta-2 adrenergic signalling, and report that clenbuterol repressed markers of muscle oxidative capacity (3-hydroxyacyl CoA dehydrogenase activity and oxidative phosphorylation complex V abundance).4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~35 h
- Bioavailability
- 90%
- Typical dose
- 20–120 mcg/day
- Route
- Oral
- Time to peak
- ~2.5 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~35 h | Terminal plasma elimination half-life of 34 hours on the German Spiropent label, estimated by compartment analysis; about 35 hours in a 1985 study in healthy volunteers, measured by enzyme immunoassay; the 2025 trial paper cites a half-life of ~25 to 35 h and the registry entry gives about 36 hr1,2,4,8 |
| Bioavailability | 90% | The German label says absorption after oral and inhaled administration is rapid and complete; the sources read give no absolute oral bioavailability figure1 |
| Time to peak | ~2.5 h | After single 20 µg or 40 µg oral doses, maximum plasma concentrations of about 0.1 and 0.2 ng/mL at 120 to 180 minutes on the German label; within 2.5 hours at 20, 40 and 80 µg in the 1985 study1,2 |
| Steady state | Not an app figure | Plasma plateau within 4 days of twice-daily dosing in the 1985 study, at 0.2 to 0.3 ng/mL on 20 µg and 0.5 to 0.6 ng/mL on 40 µg; steady-state concentrations of 0.2 to 0.3 ng/mL after 4 days on the label2,1 |
| Protein binding | Not an app figure | 89 to 98% after a single 80 µg dose in the 1985 study; 45 to 68% on the German label2,1 |
| Excretion | Not an app figure | About 20% of a single oral dose as unchanged drug in urine over 72 hours in the 1985 study; 87% in urine within 168 hours, mainly as unchanged parent compound, on the German label2,1 |
The app's half-life of 35 hours matches the 1985 estimate and differs by one hour from the label's 34 hours, and the app's note that steady state is reached in about 4 days matches both sources.2,1 The two sources differ on protein binding (89 to 98% against 45 to 68%), and the summaries read do not say why.2,1 The German label gives the onset of the bronchodilating effect after an oral dose as 5 to 20 minutes and the duration of action as up to 14 hours.1 A 1989 steady-state study in nine healthy men compared a clenbuterol tablet with a combination tablet, and its authors concluded that the apparent bioavailabilities of clenbuterol were almost identical.7
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily, as in the 2025 trial4, twice daily, as on the German label and in the 1985 study1.
An illustration from a pharmacokinetic model using a half-life of 35 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Hostrup and colleagues, Journal of Physiology 20254 | Randomised, placebo-controlled crossover; supported by Anti Doping Denmark4 | 11 healthy men aged 18 to 40; two withdrew and one completed only the first cycle4 | 80 µg a day by mouth for 2 weeks against placebo, two cycles with a 3 week washout4 | Lean mass +0.91 kg (95% CI 0.02 to 1.81), no effect on fat mass, VO2max -7%, exercise capacity -4%, no effect on sprint power output; heart rate +10 bpm 2 hours after a dose4 |
| Moesgaard and colleagues, Sports Medicine 20266 | Randomised, double-blinded, placebo-controlled; World Anti-Doping Agency grant6 | 32 healthy men (n = 16) and women (n = 16)6 | 80 µg a day against placebo during 8 weeks of resistance training, then 16 weeks of detraining and 8 weeks of retraining6 | Against placebo during 8 weeks of training: lean mass +1.7 kg, 1RM bench press +6 kg, 1RM leg press +16 kg; fat mass decrease did not differ; the lean mass difference was no longer present after detraining6 |
| Kamalakkannan and colleagues, Journal of Heart and Lung Transplantation 20085 | Small randomised controlled study5 | Patients with chronic heart failure; number not given in the text read5 | Dose and length not given in the text read5 | Significant rise in lean mass and lean/fat ratio; strength up 27% with clenbuterol and 14% with placebo; endurance and exercise duration decreased after clenbuterol5 |
| Yamamoto and colleagues, Journal of Pharmacobio-Dynamics 19852 | Single and repeated oral dose pharmacokinetics, no comparator mentioned | Healthy volunteers; number not given in the text read2 | Single 20, 40 and 80 µg; repeated twice a day2 | Half-life about 35 h, peak within 2.5 h, plateau within 4 days2 |
| Couet and colleagues, International Journal of Clinical Pharmacology, Therapy and Toxicology 19897 | Steady-state comparison of a clenbuterol tablet with a combination tablet, three occasions7 | Nine healthy men7 | 20 µg every 12 hours for 7 days7 | Apparent bioavailability of clenbuterol almost identical across formulations7 |
Deeper analysis: Hostrup and colleagues, Journal of Physiology 2025
The trial was randomised, placebo-controlled and run at the University of Copenhagen between November 2021 and December 2022, and it is registered as NCT03860870.4,8 Participants received clenbuterol hydrochloride as Spiropent tablets, or placebo tablets, in identical-looking tablets, and the authors state that allocation was concealed from assessors and participants.4 The authors write that "the main outcome measure was change in body composition (lean and fat mass) for clenbuterol" against placebo, and that sample size was set for lean mass, with 10 completers required.4 The registry entry lists blood clenbuterol concentration in dried blood spots as its primary outcome and lists body composition and aerobic capacity among secondary outcomes, with an actual enrolment of 16 and no posted results (the field reads "undefined").8 The paper says the study was part of a larger series of trials, and the registry describes two phases, a sequential first phase and a crossover second phase.4,8 Compared with placebo, clenbuterol increased lean mass by 0.91 kg (95% CI 0.02 to 1.81, P = 0.046) and did not change fat mass (0.00 kg, 95% CI -0.52 to 0.52 kg).4 Maximal oxygen uptake fell by 7% and exercise capacity by 4% with clenbuterol, with no effect on sprint power output, left ventricular mass, intravascular blood volume or haemoglobin mass.4 Within secondary and exploratory results, resting cardiac output increased by 1.3 L per minute with clenbuterol compared with placebo, heart rate was 10 beats per minute higher 2 hours after ingestion, and diastolic blood pressure was 4 mmHg lower at 2 hours, with no significant change in systolic blood pressure.4 The report names 13 eligible participants, two withdrawals and one participant who completed only the first 2 weeks, and the section headed "Participants, compliance and side effects" gives no list of individual adverse events.4 The authors describe their own limits in several places: diet and habitual physical activity were "not strictly" controlled, they write that "it cannot be excluded that ingestion of clenbuterol on trial days may have affected the performance tests", and only men aged 18 to 40 were enrolled.4 The study was supported by Anti Doping Denmark, the authors declare no competing interests, and one author (Dehnes) is affiliated with the Norwegian Doping Control Laboratory, Oslo University Hospital.4 The authors conclude that "the adverse effects of clenbuterol along with its muscle anabolic actions justify its prohibition in elite sports".4
Deeper analysis: Moesgaard and colleagues, Sports Medicine 2026
Moesgaard and colleagues, from the same University of Copenhagen group, report 32 healthy men and women who completed 8 weeks of resistance training with clenbuterol or placebo, and the trial was registered as NCT05692856; the number randomised is not given in the record read.6 Eight weeks of training were followed by 16 weeks of detraining and a further 8 weeks of resistance training, with body composition assessed by dual-energy X-ray absorptiometry and strength by leg press and bench press one-repetition maximum.6 During the first 8 weeks, clenbuterol increased gains in lean mass (+1.7 kg), 1RM bench press (+6 kg) and 1RM leg press (+16 kg) compared with placebo, with a more pronounced effect in males than in females.6 The decrease in fat mass did not differ between clenbuterol and placebo.6 After clenbuterol stopped, detraining decreased lean mass and bench press strength more in the clenbuterol group, so that the initial lean mass and bench press differences no longer separated from placebo, while the leg press difference remained.6 During the further 8 weeks of retraining, increases in lean mass and 1RM leg press did not differ between the clenbuterol and placebo groups (lean mass p = 0.393; leg press p = 0.662), while the increase in 1RM bench press was greater in the clenbuterol group (+3 kg, p = 0.047).6 The grant listed in the record is from the World Anti-Doping Agency (22C12MH), and the authors declare no conflicts of interest.6 One author (Dehnes) is affiliated with the Norwegian Doping Control Laboratory, Oslo University Hospital.6 Only the PubMed record was read for this trial, and it reports no adverse events, discontinuations, heart rate, potassium or limitations section.6
Other human data
The heart failure trial's record gives no number of participants, dose or duration in the text read, and its conclusion is that clenbuterol "was well tolerated" and that exercise training combined with clenbuterol was a planned next step.5 The 2025 trial paper's discussion describes the heart failure trial as 40 µg clenbuterol twice daily for 12 weeks with lean mass gains of around 1 kg, a figure not in the record of the heart failure trial itself.4 A ClinicalTrials.gov search for "clenbuterol" returned 14 studies, including trials in neurodegenerative disease, amyotrophic lateral sclerosis, Pompe disease, spinal and bulbar muscular atrophy and facioscapulohumeral dystrophy, and their results are not summarised here.
Doses reported in studies and on labels
These are doses stated in named studies and labels, listed for reference.
| Source | People | Dose and route | Length and comparator |
|---|---|---|---|
| Hostrup 2025 trial4 | 11 healthy men | 80 µg a day by mouth, as four 20 µg Spiropent tablets | Two 2 week cycles against placebo, 3 week washout |
| Moesgaard 2026 trial6 | 32 healthy men and women | 80 µg daily by mouth | 8 weeks with resistance training against placebo, then 16 weeks detraining and 8 weeks retraining |
| Yamamoto 1985 study2 | Healthy volunteers | Single oral doses of 20, 40 and 80 µg; repeated twice a day (plasma levels reported for 20 and 40 µg) | Single doses; repeated dosing to plateau within 4 days |
| Couet 1989 study7 | Nine healthy men | 20 µg of clenbuterol as one Spiropent tablet, alone or in a combination tablet with 30 mg ambroxol | Every 12 hours for 7 days on three occasions |
| German Spiropent label1 | Adults and children from 12 years, with chronic obstructive airway disease | 20 µg tablet: 1 tablet morning and evening unless prescribed otherwise; up to 2 x 2 tablets a day in the first 2 to 3 days with stronger breathing difficulty; daily total for adults not to exceed 5 tablets | Label dosing, no comparator |
| Case reports in athletes (systematic review)9 | 24 athletes with adverse events | Daily doses ranging from 20 µg to 30 mg, oral the most common route | Case reports and case series, no comparator |
The app's typical dose is 20 to 120 mcg/day, and the highest value is above the German label's cap of 5 tablets of 20 µg a day, which is 100 µg.1 The same label's toxicology section refers to a maximum daily dose for humans of 0.06 mg, a figure that differs from the 5 tablet cap in its dosing section.1
Side effects reported
The reports below come from trials, a systematic review of case reports, an outbreak investigation and a case report, which differ in setting and dose, and none gives a rate for a typical user. A systematic review of case reports and case series in athletes (Kumari and colleagues, International Journal of Legal Medicine, 2023) searched PubMed, Science Direct, Scopus and Google Scholar from 1990 to October 2021 and included 23 studies.9 It lists 24 athletes with adverse events, the major ones being "supraventricular tachycardia, atrial fibrillation, hypotension, chest pain, myocardial injury, myocarditis, myocardial ischemia, myocardial infarction, cardiomyopathy, hepatomegaly, hyperglycemia, and death".9 The review covers case reports and case series, the record read gives no event rate, and it states no funding.9 An investigation of 113 cases of clenbuterol poisoning in Catalonia, Spain, in 1992 (Salleras and colleagues, Public Health Reports, 1995) found that more than 50 percent had nervousness, tachycardia, muscle tremors, myalgia and headache.10 Symptoms began between 15 minutes and 6 hours after exposure and lasted between 90 minutes and 6 days, and "none of the patients died as a result of the intoxication".10 The poisoning was associated with eating veal liver, and clenbuterol was detected in 47 urine samples at 11 to 486 parts per billion but in no serum samples, so the outbreak describes food exposure and not doses taken as a drug.10 Daubert and colleagues (University of California, Davis, Journal of Medical Toxicology, 2007) described a 31-year-old man who presented about 30 minutes after a tenfold dosing error with veterinary Ventipulmin syrup.11 He had supraventricular tachycardia at a ventricular rate of 254 bpm, a potassium of 2.1 mmol/L, magnesium of 1.3 mg/dL, phosphorus of 1.0 mg/dL and glucose of 209 mg/dL, and a second ECG 16 hours after ingestion showed atrial fibrillation.11 He was electively cardioverted to sinus rhythm on hospital day 3 and discharged on oral metoprolol; "clenbuterol levels were not obtained", and the authors report that no outside funding was used.11 The German Spiropent label lists restlessness, nervousness, nausea, palpitations, tachycardia, arrhythmias, lowering or raising of blood pressure, and muscle pain and cramps among adverse reactions, and lists hypokalaemia in the rare category.1 The same list also includes tremor, headache and dizziness, and, in its cardiac section, angina-type complaints and ventricular extrasystoles in the very rare category and myocardial ischaemia with frequency not known.1 The label states that fatal outcomes have been observed after misuse of clenbuterol with other appearance- and performance-enhancing drugs, even in young adults.1 The US veterinary label states that clenbuterol "can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes", and for horses it lists mild sweating, muscle tremor, restlessness, urticaria and tachycardia in some horses during the first few days of treatment, possible elevated creatine kinase serum levels, and ataxia in 3 of 239 horses (1.3%) in clinical studies, which are animal figures.3 In the 2025 randomised trial, the heart rate change over the 2 week cycle was not significant (+4 bpm, 95% CI -1 to 8 bpm).4
Bloodwork and markers
Sources in this part
The app lists potassium, magnesium, resting heart rate, blood pressure and ECG as markers to monitor. The German Spiropent label states that serious hypokalaemia can follow beta-2 sympathomimetic treatment, that particular caution applies in patients with severe asthma because the effect can be stronger with xanthine derivatives, corticosteroids and diuretics, and that monitoring of serum potassium is recommended in such cases.1 The same label says hypokalaemia can occur after an overdose of Spiropent, so that serum potassium is to be checked, and that ECG monitoring is indicated for cardiac surveillance in poisoning.1 In the overdose case report, the measured values were potassium 2.1 mmol/L, magnesium 1.3 mg/dL, phosphorus 1.0 mg/dL, glucose 209 mg/dL and troponin I 0.23 µg/L, with a normal creatinine and a total creatine kinase of 87 U/L.11 The 2025 trial measured heart rate, blood pressure, electrocardiography and echocardiography, and reports no change in left ventricular mass or ejection fraction over the 2 week cycle.4
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List, in force from 1 January 2026, names clenbuterol under S1.2, other anabolic agents, in the class of anabolic agents prohibited at all times, in and out of competition.12 The German Spiropent label notes that use of the tablets can produce positive results in doping controls.1 Of the two clenbuterol labels a DailyMed search returned, the Ventipulmin syrup label says it is approved by FDA under NADA 140-973 for oral use in horses only, and gives the indication as management of horses with airway obstruction such as chronic obstructive pulmonary disease; the powder label was not read.3 The German Spiropent label covers 0.02 mg tablets of clenbuterol hydrochloride.1
Storage and handling
Sources in this part
What is not known
The app's 90% bioavailability is a class-based estimate, and the sources read give no absolute oral bioavailability figure; the German label says only that absorption is rapid and complete.1 Why plasma protein binding differs between the 1985 study (89 to 98%) and the German label (45 to 68%) is not explained in the text read.2,1 The longest randomised exposure in healthy adults identified is the 8 weeks in the 2026 trial, and the 2025 trial ran two 2 week cycles, so effects of longer or repeated use were not examined in those trials.4,6 The 2025 trial enrolled only men, and the 2026 trial reported a more pronounced effect in men than in women, so findings in women rest on one trial of 16 women.4,6 Rates of adverse events in healthy people taking clenbuterol are not given in the trial reports read, and the case reports and the outbreak study cannot supply them.4,9,10 The overdose case did not include a clenbuterol level, so the link between the dose taken, the low potassium and the arrhythmias in that report is not measured.11 The 2025 trial was sized for lean mass with 10 completers and its fat mass confidence interval spans -0.52 to 0.52 kg, so small effects on fat mass are not excluded by it.4
Frequently asked questions
What is the half-life of clenbuterol?
How long does clenbuterol take to reach its peak level?
How long does clenbuterol take to reach steady state?
Is clenbuterol banned by WADA?
Yes, clenbuterol is named under S1.2, other anabolic agents, on the 2026 Prohibited List, which is prohibited at all times, in and out of competition.12
Is clenbuterol approved by the FDA for people?
A DailyMed search for clenbuterol returned two labels, a clenbuterol HCl powder and Ventipulmin syrup; the Ventipulmin label reads "For oral use in horses only" and "Not for use in humans," and the powder label was not read.3
Is clenbuterol approved as a medicine anywhere?
What did the 2025 randomised trial of clenbuterol find?
Did clenbuterol change fat mass in trials?
What adverse events have been reported with clenbuterol overdose?
A review of case reports in 24 athletes, at daily doses ranging from 20 µg to 30 mg, lists supraventricular tachycardia, atrial fibrillation, hypotension, chest pain, myocardial injury, myocarditis, myocardial ischemia, myocardial infarction, cardiomyopathy, hepatomegaly, hyperglycemia and death among the major adverse events.9 One case report describes supraventricular tachycardia, a potassium of 2.1 mmol/L and later atrial fibrillation after a tenfold dosing error with a veterinary syrup.11
More in Metabolic and mitochondrial peptides
References
- Spiropent 0,02 mg Tabletten (clenbuterol hydrochloride). Fachinformation (German summary of product characteristics), Hikma document spc-de-spiropent-230901. German SmPC
- Yamamoto I, Iwata K, Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. J Pharmacobiodyn 1985;8(5):385-91. PMID 4045696
- Boehringer Ingelheim Animal Health USA Inc. Ventipulmin Syrup (clenbuterol HCl). US veterinary label, DailyMed version 6, 2022. DailyMed label
- Hostrup M, et al. Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β2-adrenergic signalling. J Physiol 2025;603(19):5529-5545. PMID 40946331
- Kamalakkannan G, et al. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transplant 2008;27(4):457-61. PMID 18374884
- Moesgaard L, et al. Effects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial. Sports Med 2026. PMID 42730843
- Couet W, et al. Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation. Int J Clin Pharmacol Ther Toxicol 1989;27(9):467-72. PMID 2807621
- University of Copenhagen. Response to Clenbuterol in Humans. ClinicalTrials.gov NCT03860870. NCT03860870
- Kumari S, et al. Adverse events of clenbuterol among athletes: a systematic review of case reports and case series. Int J Legal Med 2023;137(4):1023-1037. PMID 37062796
- Salleras L, et al. Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain. Public Health Rep 1995;110(3):338-42. PMID 7610227
- Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol 2007;3(2):56-60. PMID 18072161
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list